Every article published by PCL Research & Manufacturing: polymorph screening, solid-form selection, HPAPI containment, controlled substances, GMP analysis and company news.
13 articles
A practical, step-by-step framework for teams who need defensible solid-form data, not just a longer polymorph report.
A single diffractogram cannot confirm miscibility, physical stability, or manufacturability.
Rifaximin's polymorph dispute shows that chemical identity alone does not guarantee commercial or regulatory equivalence.
Regulators, patent examiners, and investors now expect sponsors to understand and control crystal form, not just report it after the fact.
An anonymized project shows why polymorph behavior validated at gram scale cannot be assumed to hold at kilogram scale.
When generalist CDMOs quietly outsource polymorph and crystal form work, you lose visibility, speed, and accountability.
A technical review of the specificity, linearity, and detection-limit gaps that most often trigger regulatory observations in quantitative XRPD methods.
A plain-language framework for project managers and procurement leaders deciding when a solid form is truly ready to lock.
A practical, step-by-step approach to building controlled substance analytical programs that survive the transition from discovery to GMP release.
A closer look at why rushing CMC data packages often costs more time than it saves — and what to do instead.
A practical, stage-by-stage checklist for validating XRPD, DSC/TGA, SS-NMR and Raman methods without over-investing early or scrambling late.
An anonymized case study on reconciling high-containment safety, analytical sensitivity, and audit-ready data for a cytotoxic intermediate.
A plain-language guide for program managers and procurement leaders on the business risk behind vanishing crystal forms.